ibio inc (IBIO) Key Developments
iBio, Inc. Expands Exclusive Product Collaboration With Novici Biotech LLC
Oct 22 14
iBio, Inc. and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins. IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.
Thomas A. Medsger Joins iBio, Inc.'s Clinical Advisory Board
Sep 2 14
iBio, Inc. has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board. Dr. Medsger is an expert in systemic sclerosis and localized scleroderma. Dr. Medsger will provide iBio with guidance on the further development and commercialization of the company's novel drug candidate, IBIO-CFB03, for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases.
iBio, Inc. Forms Marketing Collaboration with Kanematsu Chemicals Corporation to Target Japanese Market
Aug 14 14
iBio, Inc. and Kanematsu Chemicals Corporation, part of Kanematsu Corporation have entered into a collaboration agreement under which Kanematsu Chemicals Corporation will market the novel iBio Launch platform in Japan. The collaboration combines iBio's plant-based expression system and expertise for rapid, reliable and economical development and production of biological vaccines and therapeutics, with the marketing reach and regional expertise of the life science group from Kanematsu Chemicals Corporation. Japan commands 9% of global biologics sales (led only by the U.S. and the EU), a global market that is expected to grow to over $220 billion by 2019, according to TriMark Publications. Biologics can be categorized in three main groups: monoclonal antibodies, other therapeutic proteins, and vaccines. The iBio Launch platform has been validated for production of each of these biologics categories. The iBio Launch platform can enable companies producing either novel biologics or bio similars to achieve competitive advantages over other expression systems due to its various attributes, including lower costs and scalability.
iBio, Inc. Appoints J. Terrill Huggins to its Clinical Advisory Board
Jul 30 14
iBio, Inc. announced that it has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy. Dr. Huggins is a leading clinical investigator in the field of idiopathic pulmonary fibrosis (IPF), and has been the principal investigator or co-principal investigator in more than 20 IPF clinical trials. Dr. Huggins is associate professor of medicine in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at the Medical University of South Carolina. He also serves as the director of the Interstitial Lung Disease Program at MUSC. His research interests center on interstitial lung disease and particularly IPF. Over the past 10 years, MUSC has become one of the larges IPF clinical trials programs in the U.S., and was the high enrolling site for both recently completed Phase III trials studying the efficacy of pirfenidone and nintenanib in the treatment of IPF. Dr. Huggins has authored 33 original manuscripts, 100 plus abstracts and national presentations, and has authored 20 book chapters.
iBio, Inc. Appoints Richard M. Silver to its Clinical Advisory Board
Jul 21 14
iBio, Inc. has appointed Richard M. Silver, M.D. to its recently formed clinical advisory board. He will provide iBio with guidance on further development and clinical trial design for the company's novel drug candidate for systemic sclerosis and other fibrotic diseases.